Learn how the Beacon system’s superior cloning technology, automated imaging capabilities, and in-process quality controls provide definitive evidence of monoclonality to support regulatory approvals.
Find our how the Opto CLD workflow sets a new standard for quality, capacity, and speed in cell line development and allows CDMOs to scale operations and drive new business.
At the 2021 BPS EU virtual conference, Beacon user Joaquina Mascarenhas, PhD, at Thermo Fisher Scientific shares how the Berkeley Lights Platform enables their cell line development to move at world class speed and select the best clones.
Antibody expert, Anupam Singhal, PhD, does a 10-minute walkthrough of how the Opto™ CLD workflow makes it possible to produce superior cell lines, with >99% monoclonality assurance, in a matter of days.